Atezolizumab Plus Chemo Safe, Efficacious in Broader ES-SCLC Population
Written by
Cancer Network
Published
0
comments
0
min
The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.